RxDoctor Payments Data

Abuhuziefa Abubakr, MD

Clinical Neurophysiology · Dayton, OHNPI 1932109378

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations.

$902in general payments, 2019–2025

Across 21 payments — averaging $42.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$133
  • SK Life Science, Inc.$125
  • Amneal Pharmaceuticals LLC$117
  • Johnson & Johnson$114
  • Jazz Pharmaceuticals Inc.$89
  • Sunovion Pharmaceuticals Inc.$80
  • plus $244 from 8 others

What the payments were for

  • Food & beverage$902100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$26,914
Medicare patients
72
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levetiracetam85$4,885
Lacosamide12$2,331
Oxcarbazepine21$804
Divalproex Sodium12$255
Lamotrigine17$137

Paid to pharmacies, not to this prescriber.

Other clinical neurophysiology in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →